Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
Management
Medical & Scientific Advisory Board
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
NeuCA15-3 Test
NeuCA125 Test
EXO-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
16-Dec-2024
Weaponising Exosomes for Breast Cancer treatment
11-Dec-2024
Investor Webinar Presentation
5-Dec-2024
Disease Specificity study completed for NeuCA15-3 test
3-Dec-2024
EXO-OC test delivers outstanding performance
28-Nov-2024
2024 AGM Results of Meeting
28-Nov-2024
2024 AGM CEO Presentation
26-Nov-2024
INOVIQ receives $1m RDTI refund
31-Oct-2024
Quarterly Business Update and Appendix 4C - September 2024
25-Oct-2024
Notice of Annual General Meeting/Proxy Form
20-Sep-2024
2024 Annual Report
1
2
3
4
Next
